SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. reported a technology milestone, disclosing that it successfully completed the first robotic telesurgery performed from its bus mobile robotic telesurgery unit. This procedure was announced in a company press release and highlights the use of its robotic system in a mobile, remote-surgery setting. The press release describing the event is filed as an exhibit to the report.
Insider transactions reported for SS Innovations International, Inc. (SSII) by Sudhir Srivastava, Chairman and CEO. The filing shows two non-derivative transactions in early September 2025: on 09/03/2025 Mr. Srivastava was reported as acquiring 2,500 shares, and on 09/05/2025 he was reported as disposing of 105,000 shares. After these transactions, the total shares beneficially owned attributable to Mr. Srivastava through Sushruta Pvt. Ltd. is reported as 112,583,014 shares. The form states the holdings are indirect because the reporting person has a controlling interest in Sushruta Pvt. Ltd.
Sudhir Srivastava, identified as a Director, 10% owner and the company's Chairman and CEO, reported a series of non-derivative transactions in the common stock of SS Innovations International, Inc. (SSII) executed through an entity he controls, Sushruta Pvt. Ltd. The Form 4 shows multiple acquisitions and dispositions between 05/12/2025 and 08/11/2025, including total reported acquisitions of 60,000 shares and total reported dispositions of 111,000 shares. After the last reported transaction the beneficial ownership held indirectly by Sushruta Pvt. Ltd. is shown as 112,685,514 common shares. Table II (derivative securities) contains no entries. The filing includes an explanatory note that the reporting person has a controlling interest in Sushruta Pvt. Ltd., which holds the securities of record.
What happened: SS Innovations reported strong sales growth this quarter and in the first half of 2025, driven by system and instrument sales. Total revenue for the quarter was $10.0M and for the first six months $15.1M. Gross profit rose and operating results improved to a small positive operating income for the quarter, and the company completed an uplisting to NASDAQ.
Why it matters: The company boosted cash to $17.6M after financings and conversions, which helps near-term operations, but it still reported a $5.94M net loss for the first half and a small quarterly net loss after tax. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes dependence on related-party financing and convertible note conversions.
SS Innovations International, Inc. (Nasdaq: SSII) filed a Form 8-K dated 15 July 2025 to disclose an operational milestone. The company reports that it has now installed more than 100 SSi Mantra surgical robotic systems across India and six other countries. Collectively, the installed base has facilitated over 5,000 surgical procedures, including 240 cardiac surgeries and 32 telesurgeries.
The filing contains no revenue, earnings, guidance or transactional information; it simply furnishes the related press release as Exhibit 99.1. While financial details are absent, the figures provided highlight growing clinical adoption and an expanding geographic presence for the Mantra platform.